RAC Racura Oncology Ltd
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
Returns
| 1 day | 3.2% |
| 1 week | -6.3% |
| 1 month | -10.3% |
| 3 months | -12.7% |
| 6 months | -29.9% |
| 1 year | -51.1% |
| 3 years | 138.5% |
Risk
| Volatility (1y ann.) | 63.7% |
| Beta vs ASX 200 | 0.85 |
| Sharpe (1y) | -0.87 |
| VaR 95% (1-day) | -6.3% |
| Max drawdown (1y) | -60.4% |
| Off 1-year high | -59.1% |
Technicals
| RSI(14) | 42 |
| vs 50DMA | -6.4% |
| vs 200DMA | -19.9% |
| Trend | Death cross |
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
- Revenue—
- Gross profit—
- Operating income-$13.37M
- Net income-$11.09M
- Diluted EPS-0.06
- Free cash flow-$8.25M
- Net debt-$34.29M